Lilly’s revenue soars 48%, driven by demand of its GLP-1s
Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Read the full story at MarketWatch.com - Top Stories →
Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Read the full story at MarketWatch.com - Top Stories →
€
€
€
€